Median Technologies’ eyonis® LCS Secures CE Marking

Median Technologies has announced that its AI-based software, eyonis® LCS, has obtained CE marking for lung cancer screening, permitting its commercial distribution across the European Union. This approval follows the clearance by the U.S. FDA, expanding access to a critical tool for early cancer diagnosis. The software aids clinicians in identifying and classifying lung nodules, enhancing detection accuracy and reducing false positives and negatives. This capability supports the larger goal of implementing broad lung cancer screening initiatives across Europe.

The demand for early detection solutions is increasing as the EU sees substantial advancements in lung cancer screening programs. Countries such as Germany, France, and Italy are pioneers in these efforts, aiming to transition pilot programs to national initiatives. CEO Fredrik Brag highlights the significance of eyonis® LCS in accelerating early detection, potentially improving patient outcomes and aligning with evolving healthcare strategies.

With eyonis® LCS, Median Technologies strengthens its position in Europe, proposing a technology-driven solution to enhance clinical workflow efficiency and accuracy. This development comes at a crucial juncture as the AI-driven software aims to streamline diagnostics and support the shift to scalable, organized screening programs.